PolTREG SA, a company which we supported as part of the BRIdge Alfa pilot program, acquired two new investors. In addition to attarcting two venture capital funds from the Trigon and PAAN CAPITAL groups, the company raised PLN 2 million from PARP as part of the PARP Loan Fund. The capital will allow to start a laboratory at the turn of 2017 and 2018, which will increase the scale of the use of TREG type 1 diabetes therapy in children. The company was established with the participation of the Medical University of Gdańsk, creators of TREG method and private investors.
Acquiring investors from the capital market means ending our active role in the project. INNOventure invested in the company in December 2015 using the funds of the BRIdge Alfa Program. In addition to our funds, the company has been funded under the “Fast Track” program (by NCBR) and Horizon 2020. The next stage of financing the company will be issuing stocks on New Connect market.
More information in this article.